Nuwellis Secures $4.35M Through Equity Offering
By ATTN Desk · Editorial oversight: Sean Han
Nuwellis, Inc. (NASDAQ: NUWE)
1. Introduction
Nuwellis, Inc. (ticker: NUWE) is a medical technology company focused on fluid management solutions for patients experiencing fluid overload. The company is headquartered in Eden Prairie, Minnesota, and has been publicly traded since 2012.
2. Corporate Structure and Team
- Industry: Medical Equipment Manufacturing
- Headquarters: Eden Prairie, Minnesota
- Public Listing: Nasdaq Capital Market since 2012
- Employee Count: 51–200
- Purpose: Develop clinically proven, safe, and reliable ultrafiltration systems
- Key Product: Aquadex SmartFlow® System for the removal of excess isotonic fluid
3. Recent Developments and News
- June 10, 2025 – Filed a Form 424B4 prospectus to offer 406,755 common shares plus pre-funded and common warrants.
- Offering price: $0.30 per share
- Gross proceeds: $4.35 million
- Net proceeds: $3.96 million (after underwriting discounts)
- June 9, 2025 – SEC declared effective the registration statement for the same offering (Form S-1 Notice of Effectiveness).
- June 9, 2025 – Filed an 8-K (Items 1.01, 3.02, 5.03, 9.01); details include staffing changes and corporate updates.
- May 2025 – Signed an agreement with KDI Manufacturing to assemble Aquadex consoles and consumables.
4. Financial and Strategic Analysis
Stock Performance (as of June 11, 2025)
| Metric | Value |
|---|---|
| Share Price | $0.4983 (+112.77%) |
| Daily Volume | 56,415,044 |
| 52-Week Range | $0.21 – $8.40 |
| Market Capitalization | $1.02 million |
| Average Daily Volume (3 mo) | 1,633,319 |
Key Financial Metrics (Trailing Twelve Months)
| Metric | Value |
|---|---|
| Revenue | $8.79 million |
| Net Income (Loss) | –$9.85 million |
| Profit Margin | –112.09% |
| EPS (TTM) | 15.28 |
| PE Ratio (TTM) | 0.02 |
| Total Cash (MRQ) | $2.56 million |
| Total Debt/Equity (MRQ) | 13.73% |
Capital-Raising Initiative
- Shares & Warrants
- 406,755 common shares
- Up to 14,085,998 pre-funded warrants
- Up to 43,478,259 Series A warrants (exercise subject to stockholder approval)
- Up to 14,492,753 Series B warrants
- Use of Proceeds: Strengthen balance sheet, support operations and strategic initiatives
- Risks:
- Liquidity of pre-funded and common warrants is unestablished
- Series A warrant exercise is contingent on shareholder vote
5. Market Position and Industry Context
- Core Technology: Aquadex ultrafiltration offers an alternative to diuretics and conventional renal replacement therapies
- Applications: Heart failure, critical illness, post-operative fluid management, acute kidney injury
- Clinical Advantages: Provides precise fluid removal and is designed to reduce ICU stays
- Distribution: Deployed in hospitals across the United States and select international markets
- Competitive Landscape: Competes with diuretics, dialysis techniques, and other ultrafiltration devices
tl;dr
- June 10, 2025: Filed a $4.35 million equity and warrant offering at $0.30 per share (net proceeds ~$3.96 million).
- June 9, 2025: SEC declared the registration effective and filed an 8-K covering corporate updates.
- Stock price as of June 11, 2025 reached $0.4983 (+112.77%); volume exceeded 56 million shares.
- Announced partnership with KDI Manufacturing for Aquadex assembly capabilities.
- Future step: Obtain stockholder approval for Series A warrant exercises.